Apellis Pharmaceuticals is a biopharmaceutical company focused on the development of therapeutic compounds. Its products are used to treat disease through the inhibition of the complement system, at the level of C3, the central protein in the complement cascade. The company caters to ophthalmology, rare disease, and research areas.